Inactive Instrument

News EntreMed Inc Nasdaq

Equities

US29382F2020

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 28	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	Top Midday Gainers	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS	Apr. 08	PR
CASI Pharmaceuticals : Received Emergency Relief in connection with the Dispute with Juventas - Form 6-K	Apr. 08	PU
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS	Mar. 28	PR
CASI Pharmaceuticals : Received Notice of Termination of Commercialization Collaboration for CNCT19 from Juventas - Form 6-K	Mar. 13	PU
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	Mar. 06	AQ
Top Midday Gainers	Mar. 05	MT
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell	Mar. 05	MT
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Mar. 05	MT
Top Premarket Gainers	Mar. 05	MT
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	Mar. 05	AQ
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	Mar. 05	PR
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China	Mar. 05	CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd	Feb. 29	CI
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA	Feb. 16	PR
Casi Pharmaceuticals Announces First Dose of Folotyn in China	Feb. 16	CI
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer	Feb. 12	CI
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer	Jan. 30	CI
CASI Pharmaceuticals : Enters into Certain Agreements with respect to CASI Wuxi’s Reduction in Registered Capital and Convertible Loan - Form 6-K	Dec. 15	PU
CASI Pharmaceuticals : Enters into an Exclusive Distribution Agreement - Form 6-K	Dec. 08	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News EntreMed Inc Nasdaq

Equities

US29382F2020

Summary

Filters